SUBSCRIBE

Breaking News on Supplements & Nutrition - North AmericaEU edition

News > Research

Guest article

Resveratrol study results don’t tell the whole story on benefits: Expert

1 commentBy Joseph C. Maroon, MD , 31-Oct-2012
Last updated on 02-Nov-2012 at 14:59 GMT

Joseph C. Maroon, MD
Joseph C. Maroon, MD

A new study that concluded resveratrol does not have metabolic benefits in relatively healthy middle-aged women is "flawed" and "tells us very little about the benefits or non-benefits of resveratrol", says the chairman of GNC’s Medical Advisor Board. 

Joseph C. Maroon, MD, neurosurgeon, health and fitness expert, and chairman of GNC’s Medical Advisor Board, sent the following response to NutraIngredients-USA: 

"A recent study investigating the benefits for women of the dietary supplement resveratrol , located in the skins of red grapes and wine, found no significant improvements in insulin sensitivity or cholesterol compared to a control group.  

Bad news for resveratrol? Right? Well not exactly!

The fact is, this study from US and Italian researchers was evaluating healthy postmenopausal women who had no insulin sensitivity or cholesterol problems to start with. These post-menopausal women were actually, as a group, some of the healthiest people in this age group you could ever meet. The 15 women given a resveratrol supplement for 3 months were all in their late 50’s, were lean or overweight (not obese), and had undergone a complete medical evaluation showing no history or evidence of type 2 diabetes or cardiovascular disease. Additionally none had ever been treated or had a history of abnormal lipids (cholesterol, triglycerides, etc.) or high blood pressure.

Statistically speaking, the women investigated in this study were an extremely rare group to find and perhaps that’s why only 15 subjects were actually tested with resveratrol. The fact is the researchers would have had it much easier finding women who had diabetes, heart disease and other conditions that actually could affect metabolic performance. (See Table of common conditions in post-menopausal women)

As noted by this group of researchers, many other investigators have looked at the benefits of resveratrol in people with abnormal conditions such as metabolic syndrome (pre-diabetes), actual diabetes, heart disease and abnormal lipids, and have found significant beneficial improvements when taking this dietary supplement. In addition, the researchers conceded that prior animal studies investigating healthy animals using resveratrol (like their human study) had not shown any improvements in insulin sensitivity and blood lipid levels.

Knowing these facts, it would appear that this group of investigators had set out to find “super” results from taking resveratrol - to make normal women into “super women” who could possess even better than normal insulin sensitivity, lipid levels, and other metabolic markers. A laudable goal, but several flaws in the study design most likely prevented this from occurring.

First and foremost, the study used only 75 mg per day of essentially pure trans-resveratrol. Although others have investigated resveratrol in humans using a daily dose less than 100 mgs, most recent studies showing benefits of resveratrol have used higher dosing. In a study done in 2010 in the United Kingdom, researchers showed a dose-dependent increase in brain blood flow using resveratrol at the 250 mg and 500 mg daily dose levels. Dose-dependent means the greater the dose the greater improvement seen.

A better direct comparison to this current study was a study done in 2011 using 150 mg/day of resveratrol in healthy obese men. The researchers from the Netherlands and Switzerland found profound metabolic improvements using resveratrol in blood glucose and lipid reductions. They especially noted reductions of fat in and around the liver, which is common with obesity, and related to the development of type 2 diabetes in obesity.

By using a daily dose of only 75 mg/day of resveratrol, these non-beneficial results were most likely destined from the beginning and would not show any significant benefits compared to the placebo group. This study also had a third arm that evaluated the benefits of a calorie reduction diet (5% of body weight average loss) and any metabolic improvements. As was found in the resveratrol arm when using non-obese, healthy, post-menopausal women, no improvements were found from the already normal metabolic levels despite their significant weight loss. It’s hard to make someone significantly better who is already in good shape. 

In summary, this study, despite the media hype surrounding it, tells us very little about the benefits or non-benefits of resveratrol. Flaws in dosing (too low) and not evaluating subjects that could show improvement (healthy women) make conclusions based on this study difficult at best. 

Human studies using resveratrol will continue to fascinate both the public and media because of its great potential to improve the human condition. Get the whole story about resveratrol, then decide."

Joseph C. Maroon, M.D., F.A.C.S. is a world-renowned neurosurgeon, health and fitness expert and Ironman triathlete. He is a member of ResVitále Scientific Advisory Board, chairman of GNC’s Medical Advisor Board and senior Vice-President of the American Academy of Anti-Aging Medicine. He is the author of The Longevity Factor: How Resveratrol and Red Wine Activate Genes for a longer and Healthier Life. Dr. Maroon is the author or co-author of 40 book chapters, and author of six books in addition to more than 250 published scientific papers.

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

1 comment (Comments are now closed)

Further comment on dubious study

As I stated a week ago in response to the recently released study on resveratrol, the fault here is with the study design and protocol itself, not the resveratrol used in the study. The dosage used in this study was ridiculously low, compared to all earlier studies. In the case of the successful Albert Einstein Medical School study and the more recent Florida Pharmacology School study the dosages were approximately 10 to 20 times this amount. This dosage is consistent with the supplements used in those trials, specifically biotivia transmax and bioforte, which are readily available without a prescription. Using a dosage of only 75mg was tantamount to giving a heart attack victim one aspirin.

In all previous studies on actual type 2 diabetic patients or those suffering impaired glucose tolerance, a sign of impending diabetes, resveratrol was extremely effective in improving glucose tolerance, enhancing metabolic function and blocking the onset of diabetes.

As a cell biologist who has been involved in several human clinical trials of transmax and bioforte resveratrol against diabetes, I can only imagine that this study was designed by a pharmaceutical company to fail intentionally. The pharmas are clearly aware of the potential of resveratrol to cut into their sales of Metformin, a multi-billion dollar earner for the drug companies, and are on a campaign to discredit the compound.

As a researcher I question why the clinicians in this study would select as subjects women who have no issues with glucose tolerance, who were non-obese, and who did not exhibit signs of diabetes. This is equivalent to testing a compound designed to treat cancer on a group of subjects none of whom has cancer. Again, we see a troubling signal of possible pharma involvement.

Report abuse

Posted by James Betz
01 November 2012 | 08h40

Related products

Key Industry Events

 

Access all events listing

Our events, Events from partners...